Why Is UroGen Pharma Stock Trading Higher On Friday? - UroGen Pharma (NASDAQ:URGN)

Why Is UroGen Pharma Stock Trading Higher On Friday? - UroGen Pharma (NASDAQ:URGN)

The U.S. Food and Drug Administration (FDA) on Thursday approved UroGen Pharma Ltd.’s (NASDAQ:URGN) Zusduri, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Zusduri consists of mitomycin and sterile hydrogel, using UroGen’s proprietary sustained-release RTGel technology. Zusduri has been designed to treat potent tumor ablation. The FDA approval is …

UroGen soars 50% on FDA approval of historic bladder cancer treatment

US FDA approves UroGen's bladder cancer drug

(Reuters) -The U.S. Food and Drug Administration on Thursday approved UroGen Pharma's drug to treat a type of bladder cancer.

In surprise, FDA approves UroGen's chemo-turned-gel drug after negative adcomm vote

The FDA on Thursday approved UroGen’s application for its bladder cancer drug, despite a negative vote from an advisory committee last month. The drug, which UroGen will brand as Zusduri, is ...